XBIO News and Press, Xenetic Biosciences Inc. From 09/05/23

FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Exec...

2023-08-11 10:26:48 ET Xenetic Biosciences press release ( NASDAQ: XBIO ): Net loss for the quarter ended June 30, 2023 was approximately $1.1 million. The Company ended the quarter with approximately $10.7 million of cash and no debt. For further details see: Xe...

- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors FRAMINGHAM, MA / ACCESSWIRE / August 11, 2023 / Xenetic Biosciences, Inc. (NAS...

Live moderated video webcast on Wednesday, July 12 th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard ...

2023-05-16 11:27:04 ET Cell therapy company Xenetic Biosciences ( NASDAQ: XBIO ) trended lower Tuesday after H.C. Wainwright downgraded its shares to Neutral from Buy, citing concerns on the biotech’s catalysts path. Despite the company’s recently-announced rever...

2023-05-12 13:03:39 ET Xenetic Biosciences ( NASDAQ: XBIO ) has announced it will effect a one-for-ten reverse stock split of its outstanding common stock, effective May 15, 2023. The company expects that upon the opening of trading on May 15, 2023, its common stock will ...

- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors - Ended the quarter with $12.0 million of cash to fund operations and drive pipeline forward FRAMINGHAM, MA / A...

Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertise FRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharm...

Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planning FRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceu...

- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development - Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma FRAMINGHAM, MA / ACCESSWIRE /...